GLP-1 Microdosing: Does a Lower Dose Still Work?

Published October 7, 2026

Visit any social media or online health platform and you are sure to hear discussions about microdosing GLP-1 medications. If you have been hearing about GLP-1 microdosing, you may be wondering whether you really need to increase your medication to the usual maintenance dose.

Microdosing generally means taking a very low dose of a medication long-term. With GLP-1 medications, that might mean remaining at the starting dose of 0.25 mg of semaglutide or 2.5 mg of tirzepatide.

People may be drawn to lower doses because they are concerned about side effects or cost. Some compounded GLP-1 providers also promote very small or customized doses, which has helped fuel interest in the idea. But what do we actually know about its effectiveness?

Does GLP-1 Microdosing Cause Weight Loss?

A recent study looked retrospectively at electronic health records from a database with about 29 million patients. Researchers identified people who remained on the lowest starting dose of semaglutide or tirzepatide for at least six months.

After one year, patients on the 0.25 mg dose of semaglutide had an average weight loss of 2.2% of their initial body weight while those taking Tirzepatide 2.5 mg had an average weight loss of 5.5%.

That may sound encouraging, but we need to be careful about what these numbers mean.

The researchers were not studying people who had deliberately chosen to microdose. They identified people whose prescription records showed that they stayed on the starting dose. We don't know why their prescription was not increased.

One of the limitations of a retrospective study is that the researchers looked at what happened in their medical record, rather than assigning patients to a particular dose and following them prospectively. The study shows an association between taking the starter GLP-1 doses and the observed weight changes. It does not tell us that the low doses caused the weight loss.

The study also relied on prescription patterns as a proxy for actual medication use. A prescription record does not tell us whether someone took the medication consistently.

This study cannot tell us whether starter doses are enough for a particular person and whether they provide the same health benefits as higher doses.

The important takeaway is that this study gives us an early look at what happens when people remain on very low doses. It does not establish that intentional GLP-1 microdosing is an effective treatment strategy.

Why are people microdosing GLP-1 medications?

There are several reasons someone might want a lower dose.

Side effects are probably the most obvious. Nausea, constipation, vomiting, diarrhea and reduced appetite can make higher doses difficult to tolerate.

Cost can also matter. If someone pays out of pocket, using less medication may seem like a way to make treatment more affordable.

Some people have modest treatment goals. A person who wants to lose 10 pounds or maintain their weight after substantial weight loss may not need the same medication dosing as someone who is trying to lose 25% of their body weight.

There can also be a psychological component. A very small dose can feel safer or less intimidating than a larger dose. For some people, taking “just a little” medication may also feel more comfortable when they have internalized the stigma surrounding medications for obesity.

But the lowest dose is not automatically the right dose.

The goal is to find the dose that makes sense for your treatment goals and your tolerability.

The dose you need depends on what you are treating

This is one of the most important points about GLP-1 microdosing. Weight loss and health improvement are related but not identical.

Weight loss is not the only reason someone may be taking a GLP-1 medication. Someone focused on modest weight loss or weight maintenance may have a different treatment goal from someone using medication to address obesity-related conditions.

For example, tirzepatide has been studied at substantially higher doses for moderate-to-severe obstructive sleep apnea. Semaglutide has also been studied at a much higher dose for cardiovascular risk reduction in people with obesity or overweight and established cardiovascular disease.

So if someone is using tirzepatide specifically to treat sleep apnea, the fact that 2.5 mg produces some weight loss does not mean that the same dose adequately treats their sleep apnea.

The appropriate medication dose depends on which outcomes we are trying to achieve.

Losing weight can be an important health outcome. But the reason we treat obesity is not to produce the smallest possible number on a scale. Sometimes it is to reduce the risk of progression from prediabetes to diabetes. Sometimes it is helping a patient to walk with less knee pain.

What about compounded GLP-1 medications?

Compounded medications are sometimes marketed as a way to get very small or customized doses. But compounded semaglutide and tirzepatide are not FDA-approved products and do not undergo the FDA's premarket review for safety, effectiveness and manufacturing quality.

The FDA has also received reports of dosing errors and adverse events with compounded GLP-1 medications.

A smaller dose of a compound medication does not automatically make it safer.

So, should you microdose?

There is nothing inherently wrong with taking the lowest effective dose of medication that is appropriate for your treatment goals. But there is limited data to support intentional microdosing.

The better question is:

What dose of the medication gives you the benefit you need with side effects you can tolerate?

For some people, that may be a low dose. For others, achieving their treatment goals may require higher dosing.

The goal isn't to simply take the lowest dose. It is to find the right dose that does the job.